Immuron Phase 2 Travelan Study Misses Primary Efficacy Endpoints

Immuron reported that its Phase 2 Travelan study met safety criteria and showed a 50% reduction in ETEC challenge-related adverse events versus placebo. The study missed its primary efficacy endpoints, which the company attributed to a lower-than-expected placebo attack rate.